Navigating through the haemostatic paradox in kidney failure: A practical overview

Abstract

Summary Chronic kidney disease (CKD) affects around 9.1% of humankind globally resulting in a significant health burden. Some of these individuals will also require renal replacement therapy with dialysis due to complete kidney failure. Patients with CKD are known to be at increased risk of both bleeding and thrombosis. Often it is very difficult to manage these yin and yang since both risks tend to co‐exist. Clinically, very few studies have looked at the effects of antiplatelet agents and anticoagulants in this highly vulnerable subgroup of medical patients and evidence is very limited. This review attempts to explain the current state‐of‐the‐art regarding the basic science of haemostasis in patients with end‐stage kidney disease. We also try to transfer this knowledge into the clinics by looking at some common haemostasis challenges that are encountered in this cohort of patients and what evidence and guidance there is for their optimal management.

Anticoagulation in venous thromboembolism for the general physician

“…Patients with renal impairment and CKD are paradoxically at increased risk of both recurrent thrombosis and bleeding. 20 Furthermore, since all DOACs are partially renally cleared, there is an increased half-life in renal impairment and CKD. Patients with a creatinine clearance (CrCl) <30 ml/ min are not well represented in clinical trials, particularly those with dialysis-dependent end-stage renal disease (ESRD).…”